Did the July FDA peptide vote change the rules?

FDA's Pharmacy Compounding Advisory Committee met July 23-24, 2026 Official noticeProposed18. FDA staff recommended against placing BPC-157 on the 503A list Official notice17.

TIME reported that the committee recommended six of the seven peptides reviewed: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. It voted 6-7 against emideltide. The BPC-157 tally was 8-6 with one abstention 20. These are recommendations, not final listings 20.

The advisory vote itself did not add BPC-157 to the list or authorize compounding from it. FDA's 503A framework requires agency action. Official noticeProposed19 The status of this committee recommendation is PROPOSED, not ENACTED 20.

The advisory recommendation is separate from FDA drug approval; the vote did not approve BPC-157 as a drug 20. FDA's BPC-157 briefing evaluated the evidence for the proposed listing and recommended against it Official notice17.

Do not read a committee recommendation as a conclusion about safety or effectiveness.

In October, an HHS/FDA peptide "interim access policy" was sent to the White House/OMB for review, according to AP via STAT and Reuters 2526. It is a proposal, not a final rule. The AP report says the filing did not specify covered substances; possible BPC-157 inclusion came from unnamed sources 26.

1. TIME reports that six of seven peptides were recommended, while emideltide failed 6-7 20.
2. BPC-157 was recommended 8-6 with one abstention, and KPV was recommended 20.
3. The recommendation itself did not add BPC-157 to the 503A list or approve a drug; FDA's framework calls for rulemaking Official noticeProposed19.
4. AP and Reuters report an October interim policy proposal under White House review; its final terms and effect are not established 2526.